Modulating Microglia Activity with PPAR-γ Agonists: A Promising Therapy for Parkinson’s Disease? (original) (raw)

• Ajmone-Cat AM, Salvatori LM, De Simone R, Mancini M, Biagioni S, Bernardo A, Cacci E, Minghetti L (2012) Docosahexaenoic acid modulates inflammatory and antineurogenic functions of activated microglial cells. J Neurosci Res 90(3):575–587
  Article CAS Google Scholar
• Arai H, Furuya T, Yasuda T, Miura M, Mizuno Y, Mochizuki H (2004) Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice. J Biol Chem 279(49):51647–51653
  Article PubMed CAS Google Scholar
• Ares-Santos S, Granado N, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2012) Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45(2):810–820
  Article PubMed CAS Google Scholar
• Asanuma M, Miyazaki I (2007) Common anti-inflammatory drugs are potentially therapeutic for Parkinson’s disease? Exp Neurol 206(2):172–178
  Article PubMed CAS Google Scholar
• Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11(8):493–498
  Article PubMed Google Scholar
• Bernardo A, Minghetti L (2006) PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12(1):93–109
  Article PubMed CAS Google Scholar
• Bernardo A, Minghetti L (2008) Regulation of glial cell functions by PPAR-γ natural and synthetic agonists. PPAR Res 2008:864140
  Article PubMed CAS Google Scholar
• Bernardo A, Levi G, Minghetti L (2000) Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-δ 12,14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 12:2215–2223
  Article PubMed CAS Google Scholar
• Bower JH, Ritz B (2011) Is the answer for Parkinson disease already in the medicine cabinet?: Unfortunately not. Neurology 76(10):854–855
  Article PubMed Google Scholar
• Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α-β/δ and -γ in the adult rat. Endocrinology 137:354–366
  Article PubMed CAS Google Scholar
• Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem 82(3):615–624
  Article PubMed CAS Google Scholar
• Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119(1):182–192
  PubMed CAS Google Scholar
• Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E (2011a) Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience 194:250–261
  Article PubMed CAS Google Scholar
• Carta AR, Pisanu A, Carboni E (2011b) Do PPAR-γ agonists have a future in Parkinson’s disease therapy? Parkinsons Dis 2011:689181
  PubMed Google Scholar
• Carta AR, Pisanu A, Frau L, Spiga S, Carboni E (2011c) PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. Neurosci Abst 555.09
• Chakravarty S, Herkenham M (2005) Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci 25(7):1788–1796
  Article PubMed CAS Google Scholar
• Cimini A, Benedetti E, Cristiano L, Sebastiani P, D’Amico MA, D’Angelo B, Di Loreto S (2005) Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors RXRs in rat cortical neurons. Neuroscience 130:325–337
  Article PubMed CAS Google Scholar
• Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286(2):E252–E260
  Article PubMed CAS Google Scholar
• Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 20(2):558–567
  PubMed CAS Google Scholar
• Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909
  Article PubMed CAS Google Scholar
• Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8(6):752–758
  Article PubMed CAS Google Scholar
• De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F (2010) Chronic expression of low levels of tumor necrosis factor-α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis 37(3):630–640
  Article PubMed CAS Google Scholar
• Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88(2):494–501
  Article PubMed CAS Google Scholar
• Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5):649–688
  Article PubMed CAS Google Scholar
• Desvergne B, Michalik L, Wahli W (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18:1321–1332
  Article PubMed CAS Google Scholar
• Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK (2004) Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 148(1–2):116–126
  Article PubMed CAS Google Scholar
• Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 100(1):34–41
  Article PubMed CAS Google Scholar
• Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22(5):453–464
  Article PubMed CAS Google Scholar
• Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 205(2):295–312
  Article PubMed CAS Google Scholar
• Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70(2):177–188
  Article PubMed CAS Google Scholar
• Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi F (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. J Neurobiol Dis 24(1):183–193
  Article CAS Google Scholar
• Fetler L, Amigorena S (2005) Neuroscience. Brain under surveillance: the microglia patrol. Science 309(5733):392–393
  Article PubMed CAS Google Scholar
• Filloux F, Townsend JJ (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119(1):79–88
  Article PubMed CAS Google Scholar
• Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN (2010) Anti-apoptotic actions of PPAR-γ against ischemic stroke. Mol Neurobiol 41(2–3):180–186
  Article PubMed CAS Google Scholar
• Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M (2007) Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282(51):37006–37015
  Article PubMed CAS Google Scholar
• Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K, Nagai Y, Takatsu K, Urakaze M, Kobayashi M, Tobe K (2009) Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58(11):2574–2582
  Article PubMed CAS Google Scholar
• Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ (2010) Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10(6):453–460
  Article PubMed CAS Google Scholar
• Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21(2):404–412
  Article PubMed CAS Google Scholar
• Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330(6005):841–845
  Article PubMed CAS Google Scholar
• Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643
  PubMed CAS Google Scholar
• Granado N, O’Shea E, Bove J, Vila M, Colado MI, Moratalla R (2008) Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 107(4):1102–1112
  PubMed CAS Google Scholar
• Granado N, Ares-Santos S, O’Shea E, Vicario-Abe jón C, Colado MI, Moratalla R (2010) Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox Res 18(1):48–58
  Article PubMed Google Scholar
• Granado N, Ares-Santos S, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2011) Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 42(3):391–403
  Article PubMed CAS Google Scholar
• Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T (2009) Pioglitazone improved cognition in a pilot study on patients with Alzheimer’s disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 57(1):177–179
  Article PubMed Google Scholar
• Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res 8(5):592–606
  Article PubMed CAS Google Scholar
• Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21(7):2247–2255
  PubMed CAS Google Scholar
• Heneka MT, Landreth GE, Hüll M (2007) Drug insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders. Nat Clin Pract Neurol 3(9):496–504
  Article PubMed CAS Google Scholar
• Herrera AJ, Castaño A, Venero JL, Cano J, Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7(4):429–447
  Article PubMed CAS Google Scholar
• Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8(4):382–397
  Article PubMed CAS Google Scholar
• Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y (2001) Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 58(10):1580–1583
  Article PubMed CAS Google Scholar
• Hofmann KW, Schuh AF, Saute J, Townsend R, Fricke D, Leke R, Souza DO, Portela LV, Chaves ML, Rieder CR (2009) Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res 34(8):1401–1404
  Article PubMed CAS Google Scholar
• Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 94(14):7531–7536
  Article PubMed CAS Google Scholar
• Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100(5):1375–1386
  Article PubMed CAS Google Scholar
• Hunter RL, Choi DY, Ross SA, Bing G (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley rats. Neurosci Lett 432(3):198–201
  Article PubMed CAS Google Scholar
• Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22(2):317–330
  Article PubMed Google Scholar
• Johnston LC, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D, Hadaczek P, Federoff HJ, Bankiewicz K, Forsayeth J (2008) Human interleukin-10 gene transfer is protective in a rat model of Parkinson’s disease. Mol Ther 16(8):1392–1399
  Article PubMed CAS Google Scholar
• Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS (2006) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Biophys Res Commun 340(1):221–227
  Article PubMed CAS Google Scholar
• Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS (2007) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253(1–2):53–60
  Article PubMed CAS Google Scholar
• Kapadia R, Yi JH, Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-γ agonists. Front Biosci 13:1813–1826
  Article PubMed CAS Google Scholar
• Kaundal RK, Sharma SS (2010) Peroxisome proliferator-activated receptor-γ agonists as neuroprotective agents. Drug News Perspect 23(4):241–256
  Article PubMed CAS Google Scholar
• Kaundal RK, Iyer S, Kumar A, Sharma SS (2009) Protective effects of pioglitazone against global cerebral ischemic-reperfusion injury in gerbils. J Pharmacol Sci 109(3):361–367
  Article PubMed CAS Google Scholar
• Khairnar A, Plumitallo A, Frau L, Schintu N, Morelli M (2010) Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain. Neurotox Res 17(4):435–439
  Article PubMed CAS Google Scholar
• Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005) Peroxisome proliferator-activated receptor-γ agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191(2):331–336
  Article PubMed CAS Google Scholar
• Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ (2002) Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 941(1–2):1–10
  Article PubMed CAS Google Scholar
• Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, Lee YC (2005) Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma. Mol Pharmacol 68(6):1568–1575
  PubMed CAS Google Scholar
• Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka MT (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor-γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175(8):4948–4955
  PubMed CAS Google Scholar
• Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Członkowski A, Członkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39(3):167–180
  Article PubMed CAS Google Scholar
• Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312–318
  Article PubMed CAS Google Scholar
• Kristof AS, Fielhaber J, Triantafillopoulos A, Nemoto S, Moss J (2006) Phosphatidylinositol 3-kinase-dependent suppression of the human inducible nitric-oxide synthase promoter is mediated by FKHRL1. J Biol Chem 281(33):23958–23968
  Article PubMed CAS Google Scholar
• Kumar P, Kaundal RK, More S, Sharma SS (2009) Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson’s disease. Behav Brain Res 197(2):398–403
  Article PubMed CAS Google Scholar
• Lee SR, Kim HY, Hong JS, Baek WK, Park JW (2009) PPARγ agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun 380(1):17–21
  Article PubMed CAS Google Scholar
• Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol 89(3):277–287
  Article PubMed CAS Google Scholar
• Long-Smith CM, Collins L, Toulouse A, Sullivan AM, Nolan YM (2010) Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. J Neuroimmunol 226(1–2):20–26
  Article PubMed CAS Google Scholar
• Loughlin AJ, Woodroofe MN, Cuzner ML (1992) Regulation of Fc receptor and major histocompatibility complex antigen expression on isolated rat microglia by tumour necrosis factor, interleukin-1 and lipopolysaccharide: effects on interferon-γ induced activation. Immunology 75(1):170–175
  PubMed CAS Google Scholar
• Luchtman DW, Shao D, Song C (2009) Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson’s disease. Physiol Behav 98(1–2):130–138
  Article PubMed CAS Google Scholar
• Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation. J Biol Chem 280(22):21453–21462
  Article PubMed CAS Google Scholar
• Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J Neurochem 97(2):435–448
  Article PubMed CAS Google Scholar
• Maguire-Zeiss KA, Federoff HJ (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson’s disease. J Neural Transm 117(8):1019–1025
  Article PubMed CAS Google Scholar
• McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23(4):474–483
  Article PubMed Google Scholar
• Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson’s disease. J Neurol Sci 137(2):120–123
  Article PubMed CAS Google Scholar
• Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1–2):208–210
  Article PubMed CAS Google Scholar
• Mogi M, Kondo T, Mizuno Y, Nagatsu T (2007) p53 Protein, interferon-γ, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 414(1):94–97
  Article PubMed CAS Google Scholar
• Montero B, Ortiz J, Serra JA (2010) The role of tumor necrosis factor-α in cognitive improvement after peroxisome proliferator activated receptor γ agonist pioglitazone treatment in Alzheimer’s disease. JAGS 58(5):1000–1001
  Article Google Scholar
• Moreno S, Farioli-Vecchioli S, Cerù MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid receptors in the adult rat CNS. Neuroscience 123:131–145
  Article PubMed CAS Google Scholar
• Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a009381
  PubMed Google Scholar
• Mukherjee R, Jow L, Croston GE, Paterniti JR Jr (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272(12):8071–8076
  Article PubMed CAS Google Scholar
• Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726):1314–1318
  Article PubMed CAS Google Scholar
• Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320(3):1002–1012
  Article PubMed CAS Google Scholar
• Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J (2008) Peroxisome proliferator-activated receptors γ (PPARγ) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci 28(9):1786–1794
  Article PubMed Google Scholar
• Pereira MP, Hurtado O, Cárdenas A, Boscá L, Castillo J, Dávalos A, Vivancos J, Serena J, Lorenzo P, Lizasoain I, Moro MA (2006) Rosiglitazone and 15-deoxy-δ-12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26(2):218–229
  Article PubMed CAS Google Scholar
• Perier C, Bové J, Vila M (2012) Mitochondria and programmed cell death in Parkinson’s disease: apoptosis and beyond. Antioxid Redox Signal 16(9):883–895
  Article PubMed CAS Google Scholar
• Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6(4):193–201
  Article PubMed Google Scholar
• Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease. Brain 131(Pt 7):1880–1894
  Article PubMed Google Scholar
• Qi C, Zhu Y, Reddy JK (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32 Spring:187–204
  Article PubMed CAS Google Scholar
• Ransohoff RM, Cardona AE (2010) The myeloid cells of the central nervous system parenchyma. Nature 468(7321):253–262
  Article PubMed CAS Google Scholar
• Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–1145
  Article PubMed CAS Google Scholar
• Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23(1):55–63
  Article PubMed CAS Google Scholar
• Reynolds AD, Stone DK, Mosley RL, Gendelman HE (2009) Nitrated α-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 182:4137–4149
  Article PubMed CAS Google Scholar
• Ricote M, Glass CK (2007) PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771(8):926–935
  Article PubMed CAS Google Scholar
• Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Fernandez-Montesinos R, Caro M, Lachaud CC, Waudby CA, Delgado M, Dobson CM, Pozo D (2010) Glial innate immunity generated by non-aggregated α-synuclein in mouse: differences between wild-type and Parkinson’s disease-linked mutants. PLoS One 5(10):e13481
  Article PubMed CAS Google Scholar
• Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ (2012) Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 7(3):e33693
  Article PubMed CAS Google Scholar
• Saha P, Geissmann F (2011) Toward a functional characterization of blood monocytes. Immunol Cell Biol 89(1):2–4
  Article PubMed Google Scholar
• Saijo K, Glass CK (2011) Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 11(11):775–787
  Article PubMed CAS Google Scholar
• Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137(1):47–59
  Article PubMed CAS Google Scholar
• Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW (2009) Expression of peroxisome proliferator-activated receptor-γ in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150(2):707–712
  Article PubMed CAS Google Scholar
• Satoh N, Shimatsu A, Himeno A, Sasaki Y, Yamakage H, Yamada K, Suganami T, Ogawa Y (2010) Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 33(1):e7
  Article PubMed Google Scholar
• Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2009) Increased serum levels of soluble tumor necrosis factor-α receptor-1 in patients with Parkinson’s disease. J Neuroimmunol 216(1–2):122–125
  Article PubMed CAS Google Scholar
• Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR (2009a) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson’s disease. Neurotox Res 16(2):127–139
  Article PubMed CAS Google Scholar
• Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR (2009b) PPAR-γ mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci 29:954–963
  Article PubMed Google Scholar
• Schwartz M, Butovsky O, Brück W, Hanisch UK (2006) Microglial phenotype: is the commitment reversible? Trends Neurosci 29(2):68–74
  Article PubMed CAS Google Scholar
• Sedgwick JD, Schwender S, Imrich H, Dörries R, Butcher GW, ter Meulen V (1991) Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA 88(16):7438–7442
  Article PubMed CAS Google Scholar
• Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP (2006) Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α. FASEB J 20(6):670–682
  Article PubMed CAS Google Scholar
• Stone DK, Reynolds AD, Mosley RL, Gendelman HE (2009) Innate and adaptive immunity for the pathobiology of Parkinson’s disease. Antioxid Redox Signal 11(9):2151–2166
  Article PubMed CAS Google Scholar
• Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130(3):685–696
  Article PubMed CAS Google Scholar
• Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME (2011) The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflamm 8:91
  Article CAS Google Scholar
• Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 166(1):29–43
  Article PubMed CAS Google Scholar
• Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM (2004) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367(3):349–354
  Article PubMed CAS Google Scholar
• Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, Vemuganti R (2007) Peroxisome proliferator-activated receptor-γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 101(1):41–56
  Article PubMed CAS Google Scholar
• van Neerven S, Mey J (2007) RAR/RXR and PPAR/RXR signaling in spinal cord injury. PPAR Res 2007:29275
  PubMed Google Scholar
• Varga T, Czimmerer Z, Nagy L (2011) PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 1812:1007–1022
  Article PubMed CAS Google Scholar
• Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4(5):365–375
  Article PubMed CAS Google Scholar
• Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease. J Neurosci 21(24):9519–9528
  PubMed CAS Google Scholar
• Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11):950–958
  PubMed Google Scholar
• Xing B, Xin T, Hunter RL, Bing G (2008) Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflamm 5:4
  Article CAS Google Scholar
• Xu J, Drew PD (2007) Peroxisome proliferator-activated receptor-γ agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 178(3):1904–1913
  PubMed CAS Google Scholar
• Yasuda Y, Shimoda T, Uno K, Tateishi N, Furuya S, Yagi K, Suzuki K, Fujita S (2008) The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 204(1–2):43–51
  Article PubMed CAS Google Scholar
• Youdim MB (2010) Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson’s and Alzheimer’s diseases as disease modifying agents. Exp Neurobiol 19(1):1–14
  Article PubMed Google Scholar
• Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J (2006) Activation of cerebral peroxisome proliferator-activated receptors γ promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20(8):1162–1175
  Article PubMed CAS Google Scholar
• Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR, Global PD Gene Expression (GPEX) Consortium (2010) PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2(52):52ra73
  Article PubMed CAS Google Scholar
• Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93–104
  Article PubMed CAS Google Scholar
• Zhou Z, Peng X, Insolera R, Fink DJ, Mata M (2009) Interleukin-10 provides direct trophic support to neurons. J Neurochem 110(5):1617–1627
  Article PubMed CAS Google Scholar